IDEA Pharma and SAI MedPartners published a new China Pharmaceutical Innovation and Invention Index ranking the top 50 Chinese companies; Hengrui and BeOne led the list for invention and innovation. The report assessed R&D spending, patent filings, and approval activity to determine which firms are advancing novel medicines and bringing them to market. The index provides a new benchmark for investors and global pharma executives evaluating China’s maturing drug-development landscape and the rising competitiveness of domestic biotech players.